Updates

Multiple Research Approaches Are Key to Pandemic Preparedness, NIAID Officials Say

Rapid deployment of effective diagnostics, treatments, and vaccines may stop major disease outbreaks from potentially exploding into a pandemic. A new article by Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), examines three approaches to pandemic preparedness: pathogen-specific work, platform-based technologies, and prototype-pathogen efforts.

HHS Leverages Potential Respiratory Drug as Chemical Weapon Antidote

A potential antidote to treat the life-threatening effects of inhaled chlorine gas, a national security threat, will receive drug development support under a contract between the Biomedical Advanced Research and Development Authority, a component of the Health & Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response, and GlaxoSmithKline PLC (GSK).

DHS Blue Campaign Announces New Training for Aviation Industry

The Department of Homeland Security (DHS) and Department of Transportation have released a new human trafficking training for aviation industry personnel through the Blue Lightning Initiative. Developed by survivor advocates, law enforcement, and aviation experts, the interactive, online module outlines common indicators of human trafficking that aviation personnel may specifically encounter.

NIST’s Quick Test May Speed Antibiotic Treatment and Combat Drug Resistance

Researchers at the National Institute of Standards and Technology (NIST) have demonstrated a potential new tactic for rapidly determining whether an antibiotic combats a given infection, thus hastening effective medical treatment and limiting the development of drug-resistant bacteria. Their method can quickly sense mechanical fluctuations of bacterial cells and any changes induced by an antibiotic.

Advanced Decontamination Guidance Now Available in Alluviam’s New HazMasterG3 Release

Advanced decontamination and neutralization guidance for over 10,000 materials and tradenames, an expanded ordnance database and additional home made explosives precursors (HME) are just some of the new capabilities found in version 21 of Alluviam’s HazMasterG3 CBRNE/HME decision support system.

Information for Disaster Evacuation Centers

Natural disasters and severe weather – like the recent Hurricanes Harvey, Irma, and Maria – can result in the need for disaster evacuation centers. The Centers for Disease Control and Prevention (CDC) has assembled pertinent resources in one place.

Volunteers Play Integral Role in Disaster Relief and Recovery Efforts

Volunteers representing dozens of local, state, and national organizations are working alongside federal, state, tribal, territorial, and local responders to address the immediate needs of survivors affected by Hurricanes Irma and Harvey. The Federal Emergency Management Agency (FEMA) is advising people who want to help to do so through affiliation with the voluntary organizations that are active in the ongoing disaster operations.

HHS Partners to Develop First Intranasal Treatment for Cyanide Poisoning

The first intranasal (nose spray) treatment for the life-threatening effects of cyanide poisoning will be developed under an agreement between the U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) and Emergent BioSolutions of Gaithersburg, Maryland. Cyanide could be used as a chemical weapon against the United States.

Prepping for Rapid Drug Development

When an outbreak as virulent and fast moving as Ebola strikes, having resources to respond immediately can be the difference between life and death for both warfighters and civilians. To rapidly develop new treatments and medical countermeasures needed, the ability to conduct clinical research in a disease outbreak setting has significant advantages.

HHS Spurs New Antibiotic Development for Biodefense and Common Infections

To combat potentially deadly Clostridium difficile infections that can occur in patients being treated for bacterial infections including anthrax, tularemia and other biothreats, the U.S. Department of Health and Human Services’ (HHS) Office of the Assistant Secretary for Preparedness and Response is partnering with Summit Therapeutics on late-stage development of a new antibiotic.